Full Breakdown
Pfizer's mRNA Flu Vaccine Shows Promising Results in Phase 3 Trial
11/23/2025, 12:06:31 AM
Efficacy of the mRNA Vaccine
Pfizer's experimental mRNA flu vaccine has demonstrated superior efficacy compared to the traditional Fluzone flu vaccine in a large Phase 3 clinical trial. Published on November 19 in The New England Journal of Medicine, the study involved over 18,000 adults during the 2022-2023 flu season across the United States, South Africa, and the Philippines. Participants received either the mRNA vaccine or Fluzone, with results indicating a 34.5% reduction in flu-like illnesses among those receiving the mRNA vaccine. Specifically, there were 57 confirmed cases in the mRNA group compared to 87 in the Fluzone group, primarily caused by the H3N2 and H1N1 influenza A strains.
Side Effects and Safety Profile
While the mRNA vaccine showed improved efficacy, it also resulted in a higher incidence of side effects. Approximately 5.6% of participants receiving the mRNA vaccine reported fever, compared to 1.7% in the Fluzone group. Local reactions, such as injection site pain, were reported by 70.1% of mRNA recipients versus 43.1% of those receiving Fluzone. Despite these findings, most adverse events were mild to moderate and resolved within a few days.
Regulatory Challenges and Public Perception
Despite the promising results, the path to regulatory approval for Pfizer's mRNA flu vaccine may be complicated. Concerns regarding mRNA technology have been amplified by public skepticism, particularly from figures such as Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services. His administration has been criticized for undermining vaccine confidence, particularly regarding mRNA vaccines, which have faced unfounded claims linking them to severe health risks. In August, the U.S. Department of Health and Human Services canceled nearly $500 million in funding for mRNA vaccine research, further complicating the approval landscape.
Official Statements & Responses
Pfizer has indicated that discussions with federal regulators are ongoing, although no specific timeline for approval has been provided. Experts like Dr. Buddy Creech from Vanderbilt University Medical Center have expressed optimism about the potential of mRNA technology to enhance flu vaccine effectiveness, noting its ability to adapt more rapidly to circulating strains. However, Dr. Peter Hotez of Baylor College of Medicine has raised concerns about the current administration's lack of interest in mRNA science.
Criticism & Opposition
Critics of the mRNA vaccine technology, including anti-vaccination advocates, have propagated various myths, claiming that mRNA vaccines are more dangerous than traditional vaccines. This skepticism has tangible consequences, as seen in the delayed approval of Moderna's combination flu/COVID-19 vaccine due to additional data requests from the FDA.
What's Next
Looking ahead, both Pfizer and Moderna are expected to seek regulatory approval for their respective mRNA flu vaccines. The outcome of these applications will be closely monitored, as they could significantly impact public health strategies for future flu seasons.
